GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston ...

GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...

GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS ...

Looking to join Nucala in GSK’s collection of approved respiratory disease treatments is depemokimab, which is up for a potential December approval in severe asthma with nasal polyps.

GSK has stopped development of anti-TIGIT antibody belrestotug. The Big Pharma and its partner iTeos Therapeutics took the action after an assessment of the effect on progression-free survival ...

GSK to present data from across its respiratory portfolio at 2025 ATS International Congress in San Francisco: London, UK Monday, May 5, 2025, 10:00 Hrs [IST] GSK plc announced da ...

GSK has carried pipeline momentum into Q1, with two new U.S. approvals as highlighted. Looking ahead, we expect three more approvals for Nucala COPD, Blenrep and depemokimab this year, with PDUFA ...

Emma Walmsley, Chief Executive Officer, GSK, said, "We are very focused on preparing for launches of Blenrep, Nucala and depemokimab, and pivotal trials for potential new medicines in respiratory ...

GSK (LSE:GSK) reported a significant improvement in its first-quarter earnings, with sales, net income, and earnings per share all showing promising growth. This announcement coincided with a 5.14% ...